APOE-directed therapies are exciting avenues for future medications, and there are so many of them. Some of them are targeting lipids. CS6253 is one of them. Some of them are targeting inflammation. Others are actually targeting APOE itself. They could be targeting APOE through antibodies. They are in development and specifically towards APOE4. Other medications are trying to silence APOE4 using either ASOs or anti-oligonucleotides, antisense, or CRISPR-Cas9-targeted-based therapeutics...
APOE-directed therapies are exciting avenues for future medications, and there are so many of them. Some of them are targeting lipids. CS6253 is one of them. Some of them are targeting inflammation. Others are actually targeting APOE itself. They could be targeting APOE through antibodies. They are in development and specifically towards APOE4. Other medications are trying to silence APOE4 using either ASOs or anti-oligonucleotides, antisense, or CRISPR-Cas9-targeted-based therapeutics. The challenge here is how to get them into the brain. And finally, there is also epigenetic modification that can be cell-specific to downregulate or reduce the expression of APOE in certain cells. One of those of interest is microglia. So basically, the field is evolving quickly, targeting APOE4. Historically, we’ve had structure modifiers, and now we’ve got pathways that involve lipids, they involve inflammation, and APOE4 directly itself head-on by antibodies and by other means of reducing its expression, specifically in the brain.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
